Scholarlink

<p>Melanoma is a highly aggressive malignancy originating from melanocytes. Patients with advanced melanoma have a poor prognosis, with a high risk of distant metastasis and resistance to targeted therapy or immunotherapy. In recent years, adoptive cell therapy (ACT), an emerging personalized immunotherapy, has made significant progress in the treatment and investigation of melanoma. This review provides a comprehensive overview of ACT in melanoma, emphasizing its current application, therapeutic benefits, prevailing challenges, and future prospects, with particular focus on four major strategies: tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor-engineered T cells (TCR-T), and other immune cell-based therapies. With continuous evolution of bioengineering and precision medicine, ACT holds increasing potential for treating melanoma and other solid tumors, offering new avenues for clinical translation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Application and Advances of Adoptive Cell Therapy for Melanoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月25日

查看全文
  • Chenlu Wei,
  • Lilu Xie,
  • Chuanyuan Wei,
  • Jianying Gu

摘要

Melanoma is a highly aggressive malignancy originating from melanocytes. Patients with advanced melanoma have a poor prognosis, with a high risk of distant metastasis and resistance to targeted therapy or immunotherapy. In recent years, adoptive cell therapy (ACT), an emerging personalized immunotherapy, has made significant progress in the treatment and investigation of melanoma. This review provides a comprehensive overview of ACT in melanoma, emphasizing its current application, therapeutic benefits, prevailing challenges, and future prospects, with particular focus on four major strategies: tumor-infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR-T), T cell receptor-engineered T cells (TCR-T), and other immune cell-based therapies. With continuous evolution of bioengineering and precision medicine, ACT holds increasing potential for treating melanoma and other solid tumors, offering new avenues for clinical translation.